PONTARA, ELENA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.066
AS - Asia 3.734
EU - Europa 1.709
AF - Africa 654
SA - Sud America 615
OC - Oceania 49
Continente sconosciuto - Info sul continente non disponibili 20
Totale 13.847
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.746
SG - Singapore 1.199
CN - Cina 710
VN - Vietnam 568
BR - Brasile 391
HK - Hong Kong 373
IT - Italia 301
FI - Finlandia 192
DE - Germania 142
FR - Francia 138
SE - Svezia 114
BD - Bangladesh 99
GB - Regno Unito 88
IN - India 86
PL - Polonia 71
RU - Federazione Russa 67
IQ - Iraq 57
CI - Costa d'Avorio 56
TR - Turchia 55
ES - Italia 50
UA - Ucraina 50
AR - Argentina 49
NL - Olanda 46
CA - Canada 42
ZA - Sudafrica 37
AT - Austria 34
JP - Giappone 34
ID - Indonesia 33
MX - Messico 33
BJ - Benin 32
CO - Colombia 32
PH - Filippine 32
PK - Pakistan 30
BE - Belgio 29
IE - Irlanda 28
SA - Arabia Saudita 27
AE - Emirati Arabi Uniti 26
AZ - Azerbaigian 26
EC - Ecuador 25
HR - Croazia 25
UZ - Uzbekistan 25
EG - Egitto 24
JO - Giordania 24
MA - Marocco 24
IL - Israele 23
KR - Corea 23
VE - Venezuela 23
BY - Bielorussia 22
RS - Serbia 22
TN - Tunisia 22
AO - Angola 21
DZ - Algeria 21
ET - Etiopia 21
JM - Giamaica 21
PT - Portogallo 21
SK - Slovacchia (Repubblica Slovacca) 21
BF - Burkina Faso 19
CL - Cile 19
DK - Danimarca 19
LA - Repubblica Popolare Democratica del Laos 19
LB - Libano 19
LC - Santa Lucia 19
EE - Estonia 18
MY - Malesia 18
PY - Paraguay 18
SN - Senegal 18
YT - Mayotte 18
IR - Iran 17
NO - Norvegia 17
NP - Nepal 17
PE - Perù 17
PR - Porto Rico 17
TZ - Tanzania 17
VC - Saint Vincent e Grenadine 17
GE - Georgia 16
GT - Guatemala 16
KE - Kenya 16
PA - Panama 16
PS - Palestinian Territory 16
RO - Romania 16
TH - Thailandia 16
UG - Uganda 16
DJ - Gibuti 15
KH - Cambogia 15
KZ - Kazakistan 15
ME - Montenegro 15
ML - Mali 15
MR - Mauritania 15
UY - Uruguay 15
AD - Andorra 14
AL - Albania 14
AU - Australia 14
BA - Bosnia-Erzegovina 14
BZ - Belize 14
CG - Congo 14
HN - Honduras 14
KG - Kirghizistan 14
MW - Malawi 14
NI - Nicaragua 14
RW - Ruanda 14
Totale 13.241
Salva come PNG Salva come JPEG
Città #
Ashburn 1.026
Fairfield 782
Singapore 761
San Jose 749
Chandler 440
Woodbridge 390
Hong Kong 340
Houston 322
Cambridge 278
Seattle 277
Wilmington 245
Ann Arbor 230
Beijing 145
Ho Chi Minh City 134
Santa Clara 131
Jacksonville 120
Dong Ket 117
Hanoi 112
Boardman 99
Los Angeles 94
Princeton 90
Helsinki 86
San Diego 74
New York 61
Buffalo 58
Lauterbourg 57
Abidjan 55
Padova 55
Nanjing 51
São Paulo 50
Medford 47
Bytom 42
Orem 41
Munich 40
Roxbury 33
Milan 31
Cotonou 30
Des Moines 28
Turku 27
Chicago 25
Dublin 24
Johannesburg 24
Redondo Beach 24
Amman 23
Baghdad 23
Baku 23
Tashkent 23
Warsaw 22
Da Nang 21
Hefei 21
Atlanta 20
London 20
Vienna 20
Castries 19
Frankfurt am Main 19
Changsha 18
Dakar 18
Tokyo 18
Vientiane 18
Guangzhou 17
Kingstown 17
Brooklyn 16
Haiphong 16
Kampala 16
Tallinn 16
Washington 16
Addis Ababa 15
Minsk 15
Nuremberg 15
Rome 15
Shenyang 15
Zagreb 15
Bamako 14
Belgrade 14
Cairo 14
Council Bluffs 14
Dallas 14
Dar es Salaam 14
Kigali 14
Luanda 14
Managua 14
Montreal 14
Norwalk 14
Nouakchott 14
Ouagadougou 14
Panama City 14
Phnom Penh 14
Andorra la Vella 13
Casablanca 13
Harare 13
Jeddah 13
Madrid 13
Phoenix 13
Podgorica 13
Bishkek 12
Boston 12
Chennai 12
Denver 12
Djibouti 12
Kingston 12
Totale 8.748
Salva come PNG Salva come JPEG
Nome #
Diagnostic Value of Measuring Platelet Von Willebrand Factor in Von Willebrand Disease. 310
von Willebrand factor propeptide makes it easy to identify the shorter von Willebrand factor survival in patients with type 1 and type Vicenza von Willebrand disease. 295
Loss of cysteine 584 impairs the storage and release, but not the synthesis of von Willebrand factor 293
Predictors of relapse, death or heart transplantation in myocarditis before the introduction of immunosuppression: negative prognostic impact of female gender, fulminant onset, lower ejection fraction and serum autoantibodies 272
Usefulness of the Total Thrombus-Formation Analysis System (T-TAS) in the diagnosis and characterization of von Willebrand disease 264
Lupus anticoagulant identifies two distinct groups of patients with different antibody patterns 256
C2362F mutation gives rise to an ADAMTS13-resistant von Willebrand factor 252
A new L1446P mutation is responsible for impaired von Willebrand factor synthesis, structure, and function. 251
The p.R1819_C1948delinsS mutation makes von Willebrand factor ADAMTS13-resistant and reduces its collagen-binding capacity 245
Haemostatic patterns and bleeding scores of a genetically characterised Italian family with combined haemophilia A and type 1 von Willebrand disease 243
Abnormally large von Willebrand factor multimers in Henoch-Schönlein purpura. 239
von Willebrand factor abnormalities in aortic valve stenosis:pathophysiology and impact on bleeding. 237
Severe, recessive type 1 is a discrete form of von Willebrand disease: The lesson learned from the c.1534-3C>A von Willebrand factor mutation 236
Higher and lower active circulating VWF levels: different facets of von Willebrand disease 235
A Machine-Learning Model for the Prognostic Role of C-Reactive Protein in Myocarditis 229
A novel von Willebrand factor mutation (11372S) associated with type 2B-like von Willebrand disease: An elusive phenotype and a difficult diagnosis 229
Spontaneous hemarthrosis in combined Glanzmann thrombasthenia and type 2N von Willebrand disease. 228
Type 1 von Willebrand disease due to reduced von Willebrand factor synthesis and/or survival: observations from a case series. 226
Serum organ-specific anti-heart and anti-intercalated disk autoantibodies as new autoimmune markers of cardiac involvement in systemic sclerosis: Frequency, clinical and prognostic correlates 224
Combined exon skipping and cryptic splice activation as a new molecular mechanism for recessive type 1 von Willebrand disease. 220
Type IIB von Willebrand Factor induces phospholipase A2 activation and cytosolic Ca2+ increase in platelets 219
Reduced survival of type 2B von Willebrand factor, irrespective of large multimer representation or thrombocytopenia. 215
Microsatellite (GT)(n) repeats and SNPs in the von Willebrand factor gene promoter do not influence circulating von Willebrand factor levels under normal conditions. 210
Diagnosis and follow-up of thrombotic thrombocytopenic purpura by means of von Willebrand factor collagen binding assay. 210
Hypercortisolism and pregnancy upregulate von Willebrand factor through different mechanisms: report on a pregnant patient with Cushing's syndrome. 202
Urokinase-type plasminogen activator release after DDAVP in von Willebrand disease: different behaviour of plasminogen activators according to the synthesis of von Willebrand factor. 198
Contraceptive pills induce an improvement in congenital hypoplasminogenemia in two unrelated patients with ligneous conjunctivitis. 195
New insight into the Hypercoagulability of Cushing's Syndrome 194
Combined partial exon skipping and cryptic splice site activation as a new molecular mechanism for recessive type 1 von Willebrand disease. 194
Abnormal collagen binding activity of 2A von Willebrand factor: evidence that the defect depends only on the lack of large multimers. 193
Multiple von Willebrand factor mutations in patients with recessive type 1 von Willebrand disease. 192
Abnormalities of von Willebrand factor are also part of the prothrombotic state of Cushing's syndrome. 191
Type 2M von Willebrand disease variant characterized by abnormal von willebrand factor multimerization. 190
Acquired factor VIII:C inhibitor in a patient with Sjögren's syndrome: successful treatment with steroid and immunosuppressive therapy. 189
A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor 189
Platelet aggregation induced by plasma from type IIB von Willebrand's disease patients is associated with an increase in cytosolic Ca2+ concentration. 188
Fulminant Myocarditis: When One Size Does Not Fit All – A Critical Review of the Literature 184
An Arg760Cys mutation in the consensus sequence of the von Willebrand factor propeptide cleavage site is responsible for a new von Willebrand disease variant. 183
Inhibitory effect of prostacyclin and nitroprusside on type IIB von Willebrand factor-promoted platelet activation. 182
The Role of the Immune System in Pathobiology and Therapy of Myocarditis: A Review 179
Preliminary hemocompatibility assessment of an innovative material for blood contacting surfaces 179
Anti-phosphatidyl-serine/prothrombin antibodies (aPS/PT) in isolated lupus anticoagulant (LA): is their presence linked to dual test positivity? 177
An apparent silent nucleotide substitution (c.7056C>T) in the von Willebrand factor gene is responsible for type 1 von Willebrand disease. 177
A common ancestor more than 10,000 years old for patients with R854Q-related type 2N von Willebrand's disease in Italy. 176
EDTA dependent pseudothrombocytopenia caused by antibodies against the cytoadhesive receptor of platelet gpIIB-IIIA. 174
Lack of multimer organization of von Willebrand factor in an acquired von Willebrand syndrome. 174
Von Willebrand factor collagen binding activity in the diagnosis of von Willebrand disease: an alternative to ristocetin co-factor activity? 171
Serum Anti-Heart and Anti-Intercalated Disk Autoantibodies: Novel Autoimmune Markers in Cardiac Sarcoidosis 171
Reduced von Willebrand factor survival in type Vicenza von Willebrand disease. 170
Fainting induces an acute increase in the concentration of plasma factor VIII and von Willebrand factor. 169
Cellular Immunology of Myocarditis: Lights and Shades—A Literature Review 166
Different organization of von Willebrand factor oligomers in type-2A and -2B von Willebrand disease variants: effects of DDAVP infusion and protease inhibitors. 166
Identifying carriers of type 2N von Willebrand disease: procedures and significance. 156
First report of combined factor VII Padua defect and von Willebrand's disease due to casual association of the two defects. 155
Prevalence and Correlates of Anti-DSG2 Antibodies in Arrhythmogenic Right Ventricular Cardiomyopathy and Myocarditis: Immunological Insights from a Multicenter Study 154
Demonstration that venous occlusion fails to release von Willebrand factor multimers. 154
Post-DDAVP thrombocytopenia in type 2B von Willebrand disease is not associated with platelet consumption: failure to demonstrate glycocalicin increase or platelet activation. 154
Type I Padua: a new variant of von Willebrand's disease. 153
Which assay is the most suitable to investigate von Willebrand factor functional activity? 152
Plasma and platelet von Willebrand factor abnormalities in patients with uremia: lack of correlation with uremic bleeding. 152
A new variant of von Willebrand's disease (type I Padua): doublet-organized plasma von Willebrand factor oligomers in the presence of all size multimers. 147
The evaluation of factor VIII binding activity of von Willebrand factor by means of an ELISA method: significance and practical implications. 140
Impaired release of tissue plasminogen activator (t-PA) following DDAVP infusion in von Willebrand's disease with low platelet von Willebrand factor content. 140
Two novel mutations (Pro864His, Val867Glu) causing type 2A von Willebrand disease and affecting a single restriction site in exon 28. 140
DDAVP infusion in haemophilia A carriers: different behaviour of plasma factor VIII and von Willebrand factor. 136
Discrepant increase in factor VIII: C and von Willebrand factor after DDAVP infusion in a patient with variant von Willebrand's disease. 133
On the release of von Willebrand factor from endothelial cells after venous occlusion. 131
On the discrepant post-DDAVP increase of FVIII:C and von Willebrand factor in some patients with severe von Willebrand's disease. 123
Combined haemophilia A and type I von Willebrand's disease: a family study including an evaluation of the effects of DDAVP infusion. 122
Assessment of thrombophilia in patients with lupus anticoagulant 121
Type 2N von Willebrand disease due to Arg91Gln substitution and a cytosine deletion in exon 18 of the von Willebrand factor gene. 116
Combined hemophilia A and type 2 von Willebrand's disease: defect of both factor VIII level and factor VIII binding capacity of von Willebrand factor. 104
DDAVP infusion: a possible useful tool in the diagnosis of the haemophilia A carrier state. 94
Cardiac troponin interferents in diagnosis and clinical management of myocarditis: a single center experience. 67
Totale 13.895
Salva come PNG Salva come JPEG
Categoria #
all - tutte 39.554
article - articoli 39.554
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 79.108
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021152 0 0 0 0 0 0 0 0 0 0 0 152
2021/2022984 49 105 152 64 12 70 72 104 23 31 145 157
2022/2023832 150 105 11 114 118 115 2 54 95 7 54 7
2023/2024426 23 50 62 42 46 55 39 17 7 11 35 39
2024/20251.714 5 114 75 80 226 61 94 113 123 72 301 450
2025/20267.039 337 509 915 1.094 647 291 1.000 653 864 367 354 8
Totale 13.895